Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors
Phase 1
- Conditions
- Gastrointestinal CancerBile Duct CarcinomaEsophageal CarcinomaColorectal AdenocarcinomaGastric AdenocarcinomaPancreatic AdenocarcinomaHepatocellular Carcinoma
- Interventions
- First Posted Date
- 2018-04-25
- Last Posted Date
- 2020-07-24
- Lead Sponsor
- Curegenix Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT03507998
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
Phase 1
- Conditions
- Solid TumorsGI Cancer
- Interventions
- First Posted Date
- 2016-02-05
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- Curegenix Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT02675946
- Locations
- 🇺🇸
Memorial Care, Long Beach, California, United States
🇺🇸St. Joseph's Santa Rosa, Santa Rosa, California, United States
🇺🇸Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
News
No news found